Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Pathological Myopia Clinical Trial

Official title:
A 12 Month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Different Dosing Regimens of 0.5 mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Status Completed

Clinical Trial Summary

This study is designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (PM).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01217944
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 3
Start date	October 2010
Completion date	August 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00470977` - Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy	Phase 1/Phase 2
Completed	`NCT00407719` - Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)	Phase 1
Recruiting	`NCT03128463` - Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases	N/A
Recruiting	`NCT00155753` - Genomewide Screening of Pathological Myopia	N/A